STOCK TITAN

Olink Holding Ab (Publ) - OLK STOCK NEWS

Welcome to our dedicated page for Olink Holding Ab (Publ) news (Ticker: OLK), a resource for investors and traders seeking the latest updates and insights on Olink Holding Ab (Publ) stock.

Company Overview

Olink Holding AB (Publ) (symbol: OLK) is a specialized company dedicated to accelerating the field of proteomics. With a focus on advancing biomarker discovery and providing innovative solutions, Olink has established itself as a key contributor to modern clinical research and healthcare innovation. The company develops a platform of products and services designed to address critical needs in proteomics analysis, supporting both academic inquiry and pharmaceutical development.

Core Business Areas

Olink operates at the intersection of biotechnology and clinical research, providing a comprehensive portfolio that enables detailed protein analysis. The company specializes in:

  • Proteomics Platforms: Offering advanced tools that allow for the multiplexed analysis of protein biomarkers, thereby facilitating a deep understanding of human physiology.
  • Analytical Services: Delivering expert support and high-quality analytical services to biopharmaceutical companies and research institutions that leverage Olink's technology.
  • Research Collaboration: Partnering with leading academic and clinical organizations to drive innovative discoveries across multiple disease areas.

Market Position and Relevance

Positioned within the competitive life sciences and biotechnology industries, Olink plays a pivotal role in bridging advanced scientific research with practical healthcare applications. Its robust proteomics platform is integrated into various sectors of the healthcare ecosystem, including drug discovery, clinical diagnostics, and personalized medicine. By contributing actionable insights into cellular processes and disease biomarkers, Olink enhances the capability of researchers to make informed scientific decisions that underpin modern therapeutic strategies.

Technological Excellence

Olink’s solutions are built on cutting-edge proteomics technology that emphasizes accuracy, sensitivity, and high-throughput capability. The platform is engineered to handle the complexities of real-time human biology, offering scientists the tools necessary to detect subtle changes in protein expression. This precision technology not only supports targeted biomarker research but also contributes to a broader understanding of complex biological systems.

Global Footprint and Collaborations

Headquartered in Uppsala, Sweden, Olink has established a strong international presence with proven track records across Europe, North America, and Asia. The company collaborates with a diverse range of stakeholders including leading clinical laboratories, biopharmaceutical companies, and academic institutions. Such collaborations facilitate the integration of advanced proteomic data into research protocols and therapeutic development, underscoring Olink’s commitment to supporting global scientific innovation.

Operational Insights

The business model of Olink is built on delivering high-quality, reproducible proteomics solutions that cater to the evolving needs of the scientific community. The company emphasizes a balanced mix of product innovation and service excellence, ensuring its platform is both accessible and adaptable to a variety of research contexts. Its operations revolve around continuous refinement of assay technologies and platform integration, which in turn supports robust experimental design in clinical research settings.

Impact on Healthcare and Research

Olink’s work has significant implications for modern healthcare, particularly in the realm of early disease detection and personalized medicine. By enabling the detailed profiling of proteins, the company contributes to a deeper understanding of disease mechanisms and therapeutic response. The resulting insights drive more nuanced clinical strategies and foster innovations that improve patient outcomes without relying on speculative future outcomes.

Competitive Landscape

Within the dynamic field of biotechnology, Olink distinguishes itself through its commitment to quality data and scientific rigor. Unlike companies that emphasize volume over precision, Olink’s strategy centers on delivering precise, actionable proteomic data that equips researchers with a clearer picture of biological processes. This focus on excellence, alongside strategic collaborations with high-profile scientific institutions, reinforces its standing as a respected entity in the proteomics arena.

Conclusion

In summary, Olink Holding AB (Publ) offers a robust and scientifically validated suite of proteomics solutions that empower researchers to explore and understand the complexities of human biology. Its commitment to enhancing biomarker discovery, paired with a global, collaborative approach, cements its role as an essential player in the scientific community. The company’s integrated platform, built on technological innovation and expert application, highlights its significance in driving impactful advances in healthcare and biotechnology.

Rhea-AI Summary
Olink Holding AB (Nasdaq: OLK) launches a data library with 300,000 protein-disease risk associations from UK Biobank, aiding researchers in understanding 106 human diseases. The library, available on Olink Insight, provides insights into protein effects on disease risk and offers a tool for biomarker discovery. A technical webinar on April 24, 2024, will showcase leveraging this data for research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
none
-
Rhea-AI Summary
Olink Holding AB (OLK) reported strong financial results for the fourth quarter of 2023, with revenue reaching $68.6 million, showing an 18% year-over-year growth. Full-year revenue totaled $169.6 million, marking a 21% increase. The company ended the quarter with a cash balance of $121 million. Thermo Fisher Scientific's proposed acquisition of Olink is expected to be completed by mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
-
News
Rhea-AI Summary
Olink Holding AB (OLK) releases its Annual Report for 2023, accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
Rhea-AI Summary
Olink Holding AB announces its Annual General Meeting to be held on April 19, 2024, in Uppsala, Sweden. Shareholders must register by April 15, 2024, to attend the meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
conferences
-
Rhea-AI Summary
Olink Holding AB reschedules its 2024 Annual General Meeting to April 19th, 2024, in Uppsala, Sweden.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
Rhea-AI Summary
Thermo Fisher Scientific Inc. (TMO) reported Q4 revenue of $10.89 billion, 5% lower than the previous year. Full-year revenue was $42.86 billion, also 5% lower. GAAP diluted EPS for Q4 was $4.20, 5% higher than last year, with an adjusted EPS of $5.67, also 5% higher. The company strengthened its industry leadership, launched innovative products, and expanded its global presence. Thermo Fisher executed its capital deployment strategy, completed key acquisitions, and returned $3.5 billion to shareholders. The company initiated a guidance range for full year 2024 with revenue of $42.1 billion to $43.3 billion and adjusted EPS of $20.95 to $22.00.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
Rhea-AI Summary
Madryn Asset Management, LP (Madryn) urges SomaLogic Inc. (Nasdaq: SLGC) shareholders to vote 'AGAINST' the proposed merger with Standard BioTools Inc. (Nasdaq: LAB). Madryn holds approximately 4.2% of SomaLogic's outstanding common stock and has published a list of key questions shareholders should ask the Board of Directors regarding the Proposed Merger.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Olink Holding AB (publ) (Nasdaq: OLK) announced unaudited financial results for Q3 2023, with revenue of $44.2 million, a 39% YoY growth. Explore customer installations reached 87, and Signature Q100 placements reached 153. Q3 net loss was $(1.8) million, with adjusted EBITDA of $2.0 million. Olink exited Q3 2023 with a cash balance of $130 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
-
Rhea-AI Summary
Olink Holding AB announces that Novogene Asia Pacific Middle East and Africa has adopted the Olink Explore HT platform for next-generation proteomics technology. This partnership enhances Novogene's research services offerings and allows scientists to measure over 5,400 proteins with high specificity and sensitivity. The integration of Olink technology will provide actionable data and insights into disease biology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
none
Rhea-AI Summary
Thermo Fisher Scientific Inc. has commenced a tender offer to acquire all outstanding common shares and ADSs of Olink Holding AB for $26.00 per share and per ADS in cash. The offer will expire on November 30, 2023, and is subject to regulatory approvals and a minimum tender condition. Olink's board of directors has recommended that shareholders accept the offer. Summa Equity AB and other shareholders holding approximately 66% of Olink's shares have entered into support agreements to tender into the offer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none

FAQ

What is the current stock price of Olink Holding Ab (Publ) (OLK)?

The current stock price of Olink Holding Ab (Publ) (OLK) is $26.08 as of February 7, 2025.

What is the market cap of Olink Holding Ab (Publ) (OLK)?

The market cap of Olink Holding Ab (Publ) (OLK) is approximately 3.2B.

What is the core business of Olink Holding AB?

Olink focuses on accelerating proteomics research by providing advanced platforms and services that enable detailed protein analysis and biomarker discovery. Its offerings support both academic and biopharmaceutical research initiatives.

How does Olink generate its revenue?

Olink generates revenue primarily through the sale of its proteomics platforms, analytical services, and research collaborations. The business model centers on delivering high-quality, reproducible data to support scientific studies.

Who are the primary users of Olink's technologies?

The company serves a diverse range of stakeholders including biopharmaceutical companies, clinical research centers, and academic institutions. These users leverage Olink’s advanced proteomics data to drive research and therapeutic development.

What differentiates Olink's proteomics platform from its competitors?

Olink stands out due to its emphasis on precision, sensitivity, and high-throughput capability in protein analysis. Its technology is designed to generate reproducible, actionable data that supports in-depth biological insights without compromising on quality.

How does Olink collaborate with the scientific community?

Olink collaborates with leading academic institutions and clinical research organizations to integrate advanced proteomics data into various studies. These partnerships help facilitate innovative research and contribute to a deeper understanding of disease mechanisms.

What global markets does Olink serve?

Olink maintains a strong international presence, operating in key markets across Europe, North America, and Asia. Its global outreach ensures that researchers worldwide can access its advanced proteomics solutions.

How does Olink impact modern healthcare?

By enabling detailed profiling of protein biomarkers, Olink enhances early disease detection and supports personalized medicine approaches. This capability assists researchers and clinicians in developing more informed and effective treatment strategies.

How does Olink maintain its competitive advantage?

Olink’s competitive advantage lies in its commitment to technological innovation and scientific excellence. The company continuously refines its assays and platforms, ensuring that it provides reliable and comprehensive data that support actionable research insights.
Olink Holding Ab (Publ)

Nasdaq:OLK

OLK Rankings

OLK Stock Data

3.24B
41.90M
66.41%
35.24%
2.03%
Diagnostics & Research
Healthcare
Link
Sweden
Uppsala